pipette
ENEnglish

Extracorporeal photopheresis for the treatment of steroid-refractory immune related adverse events from immune checkpoint inhibitor therapy: a multi-center phase Ib/II clinical trial

Roxane Riemer, Lukas M. Braun, Sophie Giesler, David Ali Rafei-Shamsabadi, Sebastian Haferkamp, Alina Hartmann, Wolfgang Melchinger, Matthias Weiß, Stefanie Birth, Ulrike Philipp, Inga Gebhard, Carsten Schwänen, James A. Hutchinson, Nikolaos Karantzelis, Till Wallrabenstein, Theresa Lowinus, Niklas Brehm, Justyna Rawluk, Dietmar Pfeifer, Natascha Oßwald, Peter Bronsert, Manuel Rogg, Grigor Andreev, Melanie Boerries, Maximilian Lammer, Van Anh Nguyen, Matthias Schmuth, Natalie Köhler, Justus Duyster, Gabriele Ihorst, Philip Keye, Susana Minguet, Dirk Schadendorf, Selma Ugurel, Robert Thimme, Peter Hasselblatt, Erika L. Pearce, Burkhard Becher, Carolin Funke‐Lorenz, Florian Scherer, Bertram Bengsch, Christoph Schell, Jan-Malte Placke, Frank Meiß, Petya Apostolova, Robert Zeiser

Revista con revisión por paresUso en el mundo real

En palabras de los autores

Abstract Severe immune-related adverse events (irAE) in cancer patients receiving immune checkpoint inhibitors (ICI) require treatment interruption and immunosuppression. Based on prior preclinical data, in this prospective, single arm, non-randomized phase-Ib/II clinical trial we test the activity of Extracorporeal Photopheresis (ECP) against steroid-refractory irAEs in 30 patients (EudraCT-No.:2021-002073-26). The primary endpoint is the evaluation of the safety of ECP treatment for patients with ICI-induced irAEs. The study meets its pre-specified primary endpoint of less than 50% of patients developing ECP-related severe adverse events (SAE). No ECP-related SAE is observed and ECP-related AEs are reported in 20% (6/30) of patients. Overall response rate for all irAEs is 96.3% (CI 81.0–99.91). Colitis-, hepatitis- and dermatitis-specific response rates are 100% (13/13), 86.7% (13/15) and 100% (3/3), respectively. Secondary endpoints include the assessment of response rate of irAE and overall survival. ECP therapy is associated with reduced granzyme-A/B/K, T-bet, interferon-γ and TNF in peripheral T cells and pro-inflammatory gene-expression in the intestinal tract. The 12-month overall survival rate is 84.3% (CI 63.4%-93.8%). Response correlates with a decrease in inflammatory gene expression in the intestinal tract. These results suggest that ECP is a safe treatment option for SR-irAEs and warrant further investigation in subsequent randomized clinical trials.

Resultado principalLimitación que admiten los autores

Apareció: domingo, 25 de octubre. Nature Communications. Revista con revisión por pares.

DOI: 10.1038/s41467-026-78897-9